Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers

Biochemistry

Volumn 49, Issue 3, 2010, Pages 601-610

  Braz, Valerie A ^a   Holladay, Leslie A ^a,b   Barkley, Mary D ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSOCIATION RATE CONSTANTS; ASSOCIATION RATES; BINDING MECHANISMS; C-TERMINAL TRUNCATION; CONFORMATIONAL SELECTION; COUPLED PROCESS; DISSOCIATION RATE CONSTANT; EFAVIRENZ; EQUILIBRIUM DIALYSIS; EQUILIBRIUM DISSOCIATION CONSTANT; GEL ELECTROPHORESIS; HETERODIMERS; HIV-1 REVERSE TRANSCRIPTASE; HIV-PROTEASE; HOMODIMERS; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; PROGRESS CURVES; THERMODYNAMIC LINKAGES; TIGHT BINDING; TRYPTOPHAN FLUORESCENCE; WILD TYPES;

AMINO ACIDS; BINDING ENERGY; CRYSTAL STRUCTURE; DIALYSIS; DIMERIZATION; DIMERS; DISEASES; DISSOCIATION; ELECTROPHORESIS; EQUILIBRIUM CONSTANTS; FLUORESCENCE; MONOMERS; STOICHIOMETRY; VIRUSES;

RATE CONSTANTS;

DIMER; EFAVIRENZ; HETERODIMER; HOMODIMER; MONOMER; PROTEIN P51; PROTEIN P66; RNA DIRECTED DNA POLYMERASE; TRYPTOPHAN;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG PROTEIN BINDING; EQUILIBRIUM CONSTANT; FLUORESCENCE; GEL ELECTROPHORESIS; KINETICS; PRIORITY JOURNAL; THERMODYNAMICS; WILD TYPE;

ANTI-HIV AGENTS; BENZOXAZINES; BINDING SITES; DIMERIZATION; HIV REVERSE TRANSCRIPTASE; KINETICS; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74949132528     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi901579y     Document Type: Article

References (51)

1. di Marzo Veronese, F., Copeland, T. D., DeVico, A. L., Rahman, R., Oroszlan, S., Gallo, R. C., and Sarngadharan, M. G. (1986) Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231, 1289-1291.
2. Hizi, A., McGill, C., and Hughes, S. H. (1988) Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc. Natl. Acad. Sci. U.S.A. 85, 1218-1222.
3. Restle, T., Müller, B., and Goody, R. S. (1990) Dimerization of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 265, 8986-8988.
4. Restle, T., Müller, B., and Goody, R. S. (1992) RNase H activity of HIV reverse transcriptase is confined exclusively to the dimeric forms. FEBS Lett. 300, 97-100.
5. Le Grice, S. F. J., Naas, T., Wohlgensinger, B., and Schatz, O. (1991) Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10, 3905-3911.
6. Tsai, C. H., Lee, P. Y., Stollar, V., and Li, M. L. (2006) Antiviral therapy targeting viral polymerase. Curr. Pharm. Des. 12, 1339-1355.
7. De Clercq, E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 38, 153-179.
8. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790.
9. Ren, J., Milton, J., Weaver, K. L., Short, S. A., Stuart, D. I., and Stammers, D. K. (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8, 1089-1094.
10. Merluzzi, V. J., Hargrave, K. D., Labadia, M., Grozinger, K., Skoog, M., Wu, J. C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A. S., Faanes, R., Eckner, R. J., Koup, R. A., and Sutton, J. L. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411-1413.
11. Figueiredo, A., Moore, K. L., Mak, J., Sluis-Cremer, N., de Bethune, M.-P., and Tachedjian, G. (2006) Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog. 2, 1051-1059.
12. Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., Carroll, S. S., Pettibone, D. J., O'Brien, J. A., Ball, R. G., Balani, S. K., Lin, J. H., Chen, I.-W., Schleif, S. A., Sardana, V. V., Long, W. J., Byrnes, V. W., and Emini, E. A. (1995) L-743,726 (DMP-266):Anovel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39, 2602-2605.
13. Tachedjian, G., Orlova, M., Sarafianos, S. G., Arnold, E., and Goff, S. P. (2001) Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 98, 7188-7193.
14. Venezia, C. F., Howard, K. J., Ignatov, M. E., Holladay, L. A., and Barkley, M. D. (2006) Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. Biochemistry 45, 2779-2789.
15. Sluis-Cremer, N., Arion, D., and Parniak, M. A. (2002) Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 62, 398-405.
16. Sluis-Cremer, N., Dmitrienko, G. I., Balzarini, J., Camarasa, M.-J., and Parniak, M. A. (2000) Human immunodeficiency virus type 1 reverse transcriptase dimer destablilization by 1-{spiro[4″-amino-2″,2″-dioxo- 1″,2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]]}-3-ethylthymine. Biochemistry 39, 1427-1433.
17. Le Grice, S. F. J., Cameron, C. E., and Benkovic, S. J. (1995) Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262, 130-144.
18. Ignatov, M. E., Berdis, A. J., Le Grice, S. F. J., and Barkley, M. D. (2005) Attenuation of DNA replication by HIV-1 reverse transcriptase near the central termination sequence. Biochemistry 44, 5346-5356.
19. Tachedjian, G., Aronson, H.-E., de los Santos, M., Seehra, J., McCoy, J. M., and Goff, S. P. (2003) Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J. Mol. Biol. 326, 381-396.
20. Chen, R. F. (1967) Fluorescence quantum yields of tryptophan and tyrosine. Anal. Lett. 1, 35-42.
21. Braz, V. A., and Howard, K. J. (2009) Separation of protein oligomers by blue native gel electrophoresis. Anal. Biochem. 388, 170-172.
22. Ghosh, M., Jacques, P. S., Rodgers, D. W., Ottman, M., Darlix, J. L., and Le Grice, S. F. J. (1996) Alterations to the primer grip of p66 HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochemistry 35, 8553-8562.
23. Tachedjian, G., Aronson, H.-E. G., and Goff, S. P. (2000) Analysis of mutations and suppressors affecting interactions between subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 97, 6334-6339.
24. Vivian, J. T., and Callis, P. R. (2001) Mechanisms of tryptophan fluorescence shifts in proteins. Biophys. J. 80, 2093-2109.
25. Callis, P. R., Petrenko, A., Mui~no, P. L., and Tusell, J. R. (2007) Ab initio prediction of tryptophan fluorescence quenching by protein electric field enabled electron transfer. J. Phys. Chem. B 111, 10335-10339.
26. Divita, G., Restle, T., and Goody, R. S. (1993) Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 324, 153-158.
27. Barnard, J., Borkow, G., and Parniak, M. A. (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36, 7786-7792.
28. Venezia, C. F., Meany, B. J., Braz, V. A., and Barkley, M. D. (2009) Kinetics of association and dissociation of HIV-1 reverse transciptase subunits. Biochemistry 48, 9084-9093.
29. Copeland, R. A. (2005) Evaluation of Enzyme Inhibitors in Drug Discovery, John Wiley & Sons, New York.
30. Szedlacsek, S. E., and Duggleby, R. G. (1995) Kinetics of slow and tight-binding inhibitors. Methods Enzymol. 249, 144-180.
31. Sluis-Cremer, N., and Tachedjian, G. (2008) Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 134, 147-156.
32. Grobler, J. A., Dornadula, G., Rice, M. R., Simcoe, A. L., Hazuda, D. J., and Miller, M. D. (2007) HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J. Biol. Chem. 282, 8005-8010.
33. Lindberg, J., Sigurdsson, S., Löwgren, S., Andersson, H. O., Sahlberg, C., Noréen, R., Fridborg, K., Zhang, H., and Unge, T. (2002) Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 269, 1670-1677.
34. Xia, Q., Radzio, J., Anderson, K. S., and Sluis-Cremer, N. (2007) Probing nonnucleoside inhibitor-induced active site distortion in HIV-1 reverse transcriptase by transient kinetics analysis. Protein Sci. 16, 1728-1737.
35. Maga, G., Ubiali, D., Salvetti, R., Pregnolato, M., and Spadari, S. (2000) Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 44, 1186-1194.
36. Geitmann, M., Unge, T., and Danielson, H. (2006) Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J. Med. Chem. 49, 2375-2387.
37. Lohse, A., Hardlei, T., Jensen, A., Plesner, I. W., and Bols, M. (2000) Investigation of the slow inhibition of almond β-glucosidase and yeast isomaltase by 1-azasugar inhibitors: Evidence for the 'direct binding' model. Biochem. J. 349, 211-215.
38. Narjes, F., Brunetti, M., Colarusso, S., Gerlach, B., Koch, U., Biasiol, G., Fattori, D., De Francesco, R., Matassa, V. G., and Steinkühler, C. (2000) α-Ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry 39, 1849-1861.
39. Borkow, G., Fletcher, R. S., Barnard, J., Arion, D., Motakis, D., Dmitrienko, G. I., and Parniak, M. A. (1997) Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-napthaldehyde hydrazone. Biochemistry 36, 3179-3185.
40. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267, 988-993.
41. Wang, D.-E., Rizzo, R. C., Tirado-Rives, J., and Jorgensen, W. L. (2001) Antiviral drug design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorg. Med. Chem. Lett. 11, 2799-2802.
42. Weikl, T. R., and von Deuster, C. (2009) Selected-fit versus induced-fit protein binding: Kinetic differences and mutational analysis. Proteins 75, 104-110.
43. Pegram, L. M., and Record, M. T., Jr. (2008) Thermodynamic origin of Hofmeister ion effects. J. Phys. Chem. B 112, 9428-9436.
44. Rösgen, J.,Pettitt,B. M., and Bolen, D.W.(2005) Protein folding, stability, and solvation structure in osmolyte solutions. Biophys. J. 89, 2988-2997.
45. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr., Hughes, S. H., and Arnold, E. (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanism. Structure 4, 853-860.
46. Huang, H., Chopra, R., Verdine, G. L., and Harrison, S. C. (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 282, 1669-1675.
47. Sobolev, V., Sorokine, A., Prilusky, J., Abola, E. E., and Edelman, M. (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics 15, 327-332.
48. Willard, H. H., Merritt, L. L., Jr., and Dean, J. A. (1965) Instrumental Methods of Analysis, Vol. 256, D. Van Nostrand Company, New York.
49. Draper, N. R., and Smith,H. (1966) Applied Regression Analysis, pp 77-81, Wiley & Sons, New York.
50. Efron, B., and Tibshrirani, R. (1986) Bootstrap methods for standards errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1, 54-77.
51. Hall, P. (1992) The Bootstrap and Edgeworth Expansion, p 293, Springer-Verlag, New York.